Less than a year after the U.S. Food and Drug Administration (FDA) warned of ketoacidosis risk in patients taking a class of type 2 diabetes drugs known as SGLT2 inhibitors, the European Commission issued the same warning. Now drug authorities in both countries are urging health care providers to be vigilant and educate patients about the signs and symptoms of the serious condition. Both groups say SGLT2 inhibitors, which include Invokana and Invokamet, are effective at lowering blood sugar levels in some patients, but there is a risk for developing ketoacidosis. The condition occurs when too many ketones build up ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.